| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Outlook
Edwards is increasing its full-year total company sales growth guidance to the high end of 9% to 10%. In addition, the company is increasing its underlying growth rate guidance for TAVR to 7% to 8% from 6% to 7%. Sales guidance for the company's TMTT and Surgical product groups remains unchanged. The company is increasing its full-year EPS guidance and now expects adjusted EPS to be within the range of $2.56 to $2.62, versus previous guidance of the high end of $2.45 to $2.55. For the fourth quarter, the company projects total sales to be between $1.51 and $1.59 billion and adjusted EPS of $0.58 to $0.64.
Posted In: EW
